시장보고서

상품코드

1781996

세계의 신경퇴행성 질환 치료 시장 : 약제 유형별, 적응 질환별, 투여 경로별, 유통 경로별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2025-2032년)

Neurodegenerative Disorder Therapeutics Market, By Drug Type, By Disease Indication, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 07월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 311 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

세계의 신경퇴행성 질환 치료 시장 규모는 2024년 172억 4,390만 달러로, 2025-2032년까지 CAGR 5.80%로 확대될 것으로 예상

신경퇴행성 질환 치료 시장 - 시장 역학

노화와 표적 치료의 진보가 시장 성장을 가속

세계 인구의 고령화와 표적 치료의 비약적 진보의 융합이 신경퇴행성 질환 치료 시장을 재구성하고 있습니다. 세계보건기구(WHO)에 따르면 세계 5,500만 명 이상의 사람들이 치매를 앓고 있으며, 그 수는 2030년까지 7,800만 명, 2050년까지 1억 3,900만 명으로 증가할 것으로 예측됩니다. 이 인구 역학의 변화는 효과적인 치료법의 긴급성을 강조합니다. 미국 국립위생실험실의 브레인 이니셔티브(BRAIN Initiative)와 같은 혁신적인 연구개발은 특정 뇌와 척수의 세포를 정확하게 표적으로 하여 유전자를 활성화하는 첨단 유전자 도입 툴을 개발하여 알츠하이머병이나 파킨슨병 등의 증상에 희망을 가져왔습니다. 마찬가지로 유럽의 신경퇴행성 질환 연구 공동 프로그램(JPND)은 치료법의 진보를 가속화하기 위한 국경을 넘어선 프로젝트를 지원합니다. 이러한 협력적 노력은 혁신적인 치료와 환자 관리 개선을 통해 증대하는 신경퇴행성 질환의 부담을 해결하기 위한 것입니다.

신경퇴행성 질환 치료 시장 - 주요 인사이트

우리의 리서치 애널리스트가 공유한 분석에 따르면 세계 시장은 예측 기간(2025-2032년)에 약 5.80%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정되고 있습니다.

약물 유형별로는 콜린 에스테라아제 억제제가 2024년에 최대 시장 점유율을 나타낼 것으로 예측됐습니다.

적응 질환별로는 알츠하이머병이 2024년 주요 적응 질환이었습니다.

투여 경로별로는 경구 투여가 2024년의 주요 투여 경로였습니다.

지역별로는 북미가 2024년 최대 매출액을 기록했습니다.

신경퇴행성 질환 치료 시장 - 세분화 분석

세계의 신경퇴행성 질환 치료 시장은 약물 유형, 적응성 질환, 투여 경로, 유통 채널 및 지역에 따라 분류됩니다.

시장은 약물 유형에 따라 N-메틸 -D-아스파르트산(NMDA) 수용체 길항제, 도파민 작용제, 모노아민산화효소 B(MAO-B) 억제제, 콜린에스테라아제 억제제, 면역조절제, 선택적 세로토닌 재흡수 억제제의 6가지 범주로 분류됩니다. 콜린 에스테라아제 억제제는 인지 기능을 향상시킴으로써 알츠하이머병의 치료로 이어집니다. 도파민 작용제와 MAO-B 억제제는 파킨슨병의 증상을 관리하는 데 중요합니다. NMDA 길항제는 기억 상실을 완화하고 SSRI와 면역조절제는 신경퇴행성 질환에서 행동 증상과 염증을 지원합니다.

시장은 적응증별로 알츠하이머병, 파킨슨병, 헌팅턴병, 근위축성 측삭 경화증(ALS), 다발성 경화증(MS)의 5가지 범주로 분류됩니다. 알츠하이머병은 높은 세계 유병률의 인구동태의 고령화에 의해 우위를 차지하고 있습니다. 파킨슨병에서는 도파민을 표적으로 한 약물의 개발이 진행되고 있습니다. ALS와 헌팅턴병은 선택이 제한되어 있으며 여전히 어려움이 있습니다. 다발성 경화증은 면역 요법의 진보의 혜택을 받으며 장기 관리와 환자의 QOL이 향상되었습니다.

신경퇴행성 질환 치료 시장 - 지리적 통찰

신경퇴행성 질환 치료 시장은 건강 관리 인프라, 연구 자금, 인구 역학의 고령화 등으로 인해 지역 차이가 큽니다. 북미는 여전히 최전선에 있으며, 미국은 광범위한 임상 검사, 강력한 제약 회사, 복잡한 뇌 장애의 해명을 목적으로 한 NIH BRAIN Initiative와 같은 이니셔티브를 통해 크게 기여하고 있습니다. 유럽은 특히 독일, 프랑스, 영국 등 국가에서 JPND(신경퇴행성 질환 연구에 관한 공동 프로그램)와 같은 정부가 지원하는 프로그램이 국경을 넘어선 공동 연구를 지원하고 있습니다. 일본과 중국으로 대표되는 아시아태평양은 노인 증가와 건강 관리 지출 증가로 급속한 성장을 이루고 있습니다. 특히 일본은 세계에서도 유수의 치매 이환율에 직면하고 있으며, 선진적인 치료 개발이 진행되고 있습니다. 한편, 라틴아메리카와 중동은 인지도 향상, 정부 지원, 국제 제휴를 통해 점차 치료 범위를 확대하고 있지만, 이들 지역에서는 인프라와 접근성이 여전히 개발 과제가 되고 있습니다.

신경퇴행성 질환 치료 시장 - 경쟁 구도

신경퇴행성 질환 치료 시장 경쟁 구도는 제약 선도 및 새로운 치료 접근법에 주력하는 신흥 생명 공학 회사에 의해 형성됩니다. Biogen, Roche, Eli Lilly, Novartis 등 주요 기업들은 알츠하이머병, 파킨슨병, ALS 등의 질환에 대한 표적 생물제제, 유전자 치료, 단일클론항체의 개발을 주도하고 있습니다. 예를 들어, 아밀로이드를 표적으로 하는 Biogen의 치료는 규제 당국의 결과가 틀림없음에도 불구하고 세계의 주목을 받고 있습니다. 동시에 소규모 생명공학 신흥기업도 RNA 기반 치료, 줄기세포 치료, 신경보호제를 추진하고 있으며, 많은 경우 학술기관과 정부기관과의 공동연구에 의해 지원되고 있습니다. 전략적 제휴, 라이선싱 계약, 공동 연구 프로그램이 일반적이며, 이는 신경퇴행 치료의 임상검사의 높은 실패율을 극복하는 것을 기업이 목표로 하고 있기 때문입니다. 특히 미국과 EU에서는 관민 파트너십이 혁신의 파이프라인을 촉진하고 이 고위험 고수요 치료 영역에서 초기 단계의 발견과 후기 단계의 임상적 성공의 교대를 지원하고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 신경퇴행성 질환 치료 산업

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 프로파일
- AbbVie Inc.
- ACADIA Pharmaceuticals Inc.
- Alector Inc.
- Allergan PLC
- Amylyx Pharmaceuticals Inc.
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- H. Lundbeck A/S
- Merck Serono SA
- Mitsubishi Tanabe Pharma Corporation
- Novartis International AG
- Orion Corporation
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- 기타

제13장 애널리스트의 전방위적 전망

JHS 25.08.11

REPORT HIGHLIGHT

Neurodegenerative Disorder Therapeutics Market size was valued at US$ 17,243.90 Million in 2024, expanding at a CAGR of 5.80% from 2025 to 2032.

The Neurodegenerative Disorder Therapeutics Market encompasses treatments aimed at managing or slowing the progression of chronic neurological conditions such as Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis (ALS). Rising life expectancy and aging populations worldwide are contributing to a growing patient base, with the World Health Organization estimating that over 55 million people currently live with dementia globally. Despite this, therapeutic development faces significant barriers, including high clinical trial failure rates and the complex nature of neurodegeneration. Limited understanding of disease mechanisms and the blood-brain barrier challenge effective drug delivery. However, the market is witnessing increased investment in gene therapy, monoclonal antibodies, and RNA-based treatments, offering hope for more targeted interventions. Initiatives by national health agencies, such as the U.S. NIH's BRAIN Initiative and Europe's Joint Programme on Neurodegenerative Disease Research (JPND), are creating collaborative frameworks that accelerate innovation and therapeutic advancements in this space.

Neurodegenerative Disorder Therapeutics Market- Market Dynamics

Aging Population and Advancements in Targeted Therapies to Propel Market Growth

The convergence of an aging global population and breakthroughs in targeted therapies is reshaping the neurodegenerative disorder therapeutics market. According to the World Health Organization, over 55 million people worldwide are living with dementia, a number projected to rise to 78 million by 2030 and 139 million by 2050. This demographic shift underscores the urgency for effective treatments. Innovative research initiatives, such as the U.S. National Institutes of Health's BRAIN Initiative, have developed advanced gene delivery tools that precisely target and activate genes in specific brain and spinal cord cells, offering hope for conditions like Alzheimer's and Parkinson's. Similarly, Europe's Joint Programme on Neurodegenerative Disease Research (JPND) supports transnational projects to accelerate therapeutic advancements. These collaborative efforts aim to address the growing burden of neurodegenerative diseases through innovative treatments and improved patient care.

Neurodegenerative Disorder Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2025-2032)

Based on Drug Type segmentation, Cholinesterase inhibitors were predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Route of Administration segmentation, Oral Administration was the leading Route of Administration in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neurodegenerative Disorder Therapeutics Market- Segmentation Analysis:

The Global Neurodegenerative Disorder Therapeutics Market is segmented on the basis of Drug Type, Disease Indication, Route of Administration, Distribution Channel, and Region.

The market is divided into six categories based on Drug Type: N-methyl-D-aspartate (NMDA) Receptor Antagonists, Dopamine Agonists, Monoamine Oxidase-B (MAO-B) Inhibitors, Cholinesterase Inhibitors, Immunomodulators, and Selective Serotonin Reuptake Inhibitors. Cholinesterase inhibitors lead to Alzheimer's care by boosting cognitive function. Dopamine agonists and MAO-B inhibitors are key in managing Parkinson's symptoms. NMDA antagonists help moderate memory loss, while SSRIs and immunomodulators support behavioral symptoms and inflammation in neurodegenerative conditions.

The market is divided into five categories based on Disease Indication: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS). Alzheimer's disease dominates due to high global prevalence and aging demographics. Parkinson's sees strong therapeutic development with dopamine-targeting drugs. ALS and Huntington's remain challenging with limited options. Multiple Sclerosis benefits from immunotherapy advancements, improving long-term management and patient quality of life.

Neurodegenerative Disorder Therapeutics Market- Geographical Insights

The Neurodegenerative Disorder Therapeutics Market demonstrates significant regional variation, driven by healthcare infrastructure, research funding, and aging demographics. North America remains at the forefront, with the United States contributing majorly through extensive clinical trials, strong pharmaceutical presence, and initiatives like the NIH BRAIN Initiative aimed at decoding complex brain disorders. Europe follows closely, particularly in countries like Germany, France, and the UK, where government-backed programs such as JPND (Joint Programme on Neurodegenerative Disease Research) support cross-border research collaborations. The Asia-Pacific region, led by Japan and China, is experiencing rapid growth due to rising elderly populations and increased healthcare spending. Japan, in particular, faces one of the world's highest dementia rates, prompting advanced therapeutic development. Meanwhile, Latin America and the Middle East are gradually expanding their therapeutic reach through growing awareness, government support, and international partnerships, though infrastructure and accessibility remain developmental challenges in these regions.

Neurodegenerative Disorder Therapeutics Market- Competitive Landscape:

The competitive landscape of the Neurodegenerative Disorder Therapeutics Market is shaped by both pharmaceutical giants and emerging biotech firms focusing on novel treatment approaches. Companies like Biogen, Roche, Eli Lilly, and Novartis are leading efforts in the development of targeted biologics, gene therapies, and monoclonal antibodies for conditions such as Alzheimer's, Parkinson's, and ALS. Biogen's work on amyloid-targeting therapies, for instance, has sparked global attention despite mixed regulatory outcomes. Simultaneously, smaller biotech startups are advancing RNA-based treatments, stem cell therapies, and neuroprotective agents, often supported by collaborations with academic institutions and government bodies. Strategic alliances, licensing agreements, and joint research programs are common, as firms aim to overcome the high failure rates of neurodegenerative drug trials. Public-private partnerships, particularly in the U.S. and EU, are fostering innovation pipelines, helping bridge early-stage discoveries and late-stage clinical success in this high-risk, high-need therapeutic domain.

Recent Developments:

In April 2025, Transneural Therapeutics, a preclinical-stage biotech firm, introduced innovative neuroplastogens aimed at transforming treatment for neuropsychiatric disorders. These new compounds offer a safer, more effective alternative to traditional psychedelics, marking a breakthrough in next-generation mental health therapies.

In May 2025, Sanofi announced the acquisition of Vigil Neuroscience, adding VG-3927, an investigational oral TREM2 agonist for Alzheimer's disease, to its neurology pipeline. This move strengthens Sanofi's commitment to developing innovative neurodegenerative disorder therapeutics.

In May 2025, ABLi Therapeutics launched with a focus on developing treatments for neurodegenerative diseases arising from c-Abl kinase activation. Their lead candidate, Risvodetinib (ABLi-148009), is a potent, brain-penetrant, selective c-Abl kinase inhibitor designed for once-daily oral use, aiming to halt or reverse Parkinson's disease progression.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.
ACADIA Pharmaceuticals Inc.
Alector Inc.
Allergan PLC
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Boehringer Ingelheim International GmbH
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline PLC
H. Lundbeck A/S
Merck Serono S.A.
Mitsubishi Tanabe Pharma Corporation
Novartis International AG
Orion Corporation
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.s
Others

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

N-methyl-D-aspartate (NMDA) Receptor Antagonists
Dopamine Agonists
Monoamine Oxidase-B (MAO-B) Inhibitors
Cholinesterase Inhibitors
Immunomodulators
Selective Serotonin Reuptake Inhibitor

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple Sclerosis (MS)

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Transdermal

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Neurodegenerative Disorder Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Neurodegenerative Disorder Therapeutics Market Snippet by Drug Type
- 2.1.2. Neurodegenerative Disorder Therapeutics Market Snippet by Disease Indication
- 2.1.3. Neurodegenerative Disorder Therapeutics Market Snippet by Route of Administration
- 2.1.4. Neurodegenerative Disorder Therapeutics Market Snippet by Distribution Channel
- 2.1.5. Neurodegenerative Disorder Therapeutics Market Snippet by Country
- 2.1.6. Neurodegenerative Disorder Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. Neurodegenerative Disorder Therapeutics Key Market Trends

3.1. Neurodegenerative Disorder Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Neurodegenerative Disorder Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Neurodegenerative Disorder Therapeutics Market Opportunities
3.4. Neurodegenerative Disorder Therapeutics Market Future Trends

4. Neurodegenerative Disorder Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Neurodegenerative Disorder Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Neurodegenerative Disorder Therapeutics Market Landscape

6.1. Neurodegenerative Disorder Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Neurodegenerative Disorder Therapeutics Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
- 7.1.2. N-methyl-D-aspartate (NMDA) Receptor Antagonists
- 7.1.3. Dopamine Agonists
- 7.1.4. Monoamine Oxidase-B (MAO-B) Inhibitors
- 7.1.5. Cholinesterase Inhibitors
- 7.1.6. Immunomodulators
- 7.1.7. Selective Serotonin Reuptake Inhibitor

8. Neurodegenerative Disorder Therapeutics Market - By Disease Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
- 8.1.2. Alzheimer's Disease
- 8.1.3. Parkinson's Disease
- 8.1.4. Huntington's Disease
- 8.1.5. Amyotrophic Lateral Sclerosis (ALS)
- 8.1.6. Multiple Sclerosis (MS)

9. Neurodegenerative Disorder Therapeutics Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Injectable
- 9.1.4. Transdermal

10. Neurodegenerative Disorder Therapeutics Market - By Distribution Channel

10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 10.1.2. Hospital Pharmacies
- 10.1.3. Retail Pharmacies
- 10.1.4. Online Pharmacies

11. Neurodegenerative Disorder Therapeutics Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neurodegenerative Disorder Therapeutics Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. ACADIA Pharmaceuticals Inc.
- 12.2.3. Alector Inc.
- 12.2.4. Allergan PLC
- 12.2.5. Amylyx Pharmaceuticals Inc.
- 12.2.6. Biogen Inc.
- 12.2.7. Boehringer Ingelheim International GmbH
- 12.2.8. Celgene Corporation
- 12.2.9. Eli Lilly and Company
- 12.2.10. F. Hoffmann-La Roche Ltd.
- 12.2.11. GlaxoSmithKline PLC
- 12.2.12. H. Lundbeck A/S
- 12.2.13. Merck Serono S.A.
- 12.2.14. Mitsubishi Tanabe Pharma Corporation
- 12.2.15. Novartis International AG
- 12.2.16. Orion Corporation
- 12.2.17. Pfizer Inc.
- 12.2.18. Sanofi S.A.
- 12.2.19. Teva Pharmaceutical Industries Ltd.
- 12.2.20. UCB S.A.
- 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us